Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech podcast ...

While Pfizer insisted on making overall survival as a primary endpoint across all its phase 3 trials of its PD-1xVEGF drug, BioNTech and BMS recently revised the design for pumitamig's first-line ...

While the document circulating is authentic, it is not a list of side effects of Pfizer's mRNA vaccine against COVID-19. It is a list of adverse events of special interest. Adverse events are unwanted ...

BioNTech BNTX-0.04%decrease; down pointing triangle plans to shrink its workforce and manufacturing network, as the German biotech company seeks to cut costs and downsize its footprint after demand ...

Pfizer Inc. (NYSE:PFE) is one of the 10 Best Medical Stocks to Buy Under $30. On April 20, Pfizer Inc. (NYSE:PFE) announced, together with Astellas Pharma Inc., that the US Food and Drug ...

Invited commentary of Gadelha CSE et al. Immunogenicity and safety of BNT162b2 vaccine in patients with juvenile immune-mediated inflammatory disease. Pediatric Research (2026). With more than 700,000 ...

Pfizer and BioNTech have halted a U.S. study of their updated COVID-19 vaccine in adults ages 50-64 due to slow enrollment, a Pfizer spokesperson confirmed to Becker’s. “We can confirm our ...

LONDON, April 1 (Reuters) - Vaccine makers Pfizer and BioNTech halted a large U.S. trial of their updated COVID-19 vaccine in healthy adults aged 50 to 64, saying enrollment in the trials had been too ...

Pfizer (PFE) and BioNTech (BNTX) have halted recruitment for a large U.S.-based clinical trial designed to test their updated COVID-19 vaccine in healthy adults aged 50-64 years, citing challenges in ...

LONDON, April 1 (Reuters) - Vaccine makers Pfizer (PFE.N), opens new tab and BioNTech (22UAy.DE), opens new tab halted a large U.S. trial of their updated COVID-19 vaccine in healthy adults aged 50 to ...

Pfizer is working to get approval on a new vaccine that could protect people against Lyme disease, but the company could see pushback from the government following studies done on the vaccine. "What ...